Market Overview

Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit

Share:

TAC technology shows efficacy, safety, and TAC-T cell persistence in
preclinical models of liquid and solid tumors

Triumvira
Immunologics, Inc. (Triumvira),
a privately-held biopharmaceutical
company focused on designing safe and more effective T cell therapies,
will present data today on its novel T cell therapy technology, TAC-T,
during an oral presentation in the Adoptive T Cell Therapies
session of the 6th
Annual Immuno-Oncology Summit
held in Boston. The presentation will
describe the differentiated mechanism of action of the company's T cell
antigen coupler (TAC) technology in preclinical studies demonstrating
strong efficacy in both solid and liquid tumors with an improved safety
profile compared to traditional CAR-T approaches.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180830005170/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

The oral presentation, entitled: TAC-T: a novel T cell therapy,
co-opts the endogenous T cell receptor for effective, safe, and
persistent tumor rejection,
will be delivered by Christopher Helsen,
PhD, Director of Research and Development at Triumvira. Results from
pre-clinical studies with human T cells engineered with Triumvira's
proprietary TAC
technology
directed against different antigens will be presented.
The data suggest that TAC-T cells destroy tumor cells via a mechanism
that mimics the natural process of T cell activation. Results clearly
demonstrate efficient infiltration and proliferation in solid tumors
resulting in rapid and sustained tumor regression in mice without
toxicity. Furthermore, in a xenograft model of multiple myeloma, treated
mice showed resistance to tumor re-challenge indicating long-term
persistence of TAC-T cells.

"These results will further illustrate the potential of TAC-T cells,
both in terms of efficacy and safety but also with respect to TAC T-cell
persistence, a key point under consideration in T cell therapy," said
Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th
Annual International Partnering Conference BioPharm America
on
September 5-6 and the 4th
Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell
Immunotherapies
on September 4-5, both being held during Biotech
Week Boston. For more information, or to set up a meeting with Triumvira
at either conference email: partners@triumvira.com.

About Triumvira Immunologics
Triumvira Immunologics, Inc. is
an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at
McMaster University and Bloom Burton & Co., a niche life-sciences
investment bank, with the vision of developing novel T cell therapies
that are safer and more efficacious than current cell therapy cancer
treatments, including chimeric antigen receptor (CAR) and engineered T
cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler
(TAC) technology recruits the entire natural T cell receptor and is
independent of the Major Histocompatibility Complex (MHC), allowing for
the development of better therapies for a broader range of patients with
either solid or liquid malignancies and with diseases other than cancer.
With operations spanning North America, our corporate offices are
located in Austin, Texas, and our research facilities in Hamilton,
Ontario. For more information, visit www.triumvira.com
or send email inquiries to partners@triumvira.com.

View Comments and Join the Discussion!